Searching News Database: melanoma
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HSMN NewsFeed - 22 Jun 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 23 Jul 2020
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
HSMN NewsFeed - 23 Jun 2020
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
HSMN NewsFeed - 26 Mar 2020
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte(R) RAPID
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte(R) RAPID
HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 14 Feb 2020
Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
HSMN NewsFeed - 2 Sep 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
HSMN NewsFeed - 24 Apr 2019
Xstrahl Spotlights Full Range of X-Ray Therapy and Radiation Research Systems at ESTRO 2019
Xstrahl Spotlights Full Range of X-Ray Therapy and Radiation Research Systems at ESTRO 2019
HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
HSMN NewsFeed - 5 Nov 2018
Biocept Announces New Executive Hires to its Sales and Marketing Organization
Biocept Announces New Executive Hires to its Sales and Marketing Organization
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 10 Sep 2018
Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
HSMN NewsFeed - 11 Jun 2018
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
HSMN NewsFeed - 8 May 2018
Sensus Healthcare Appoints Dr. Isabelle Raymond as Vice President, Clinical Development
Sensus Healthcare Appoints Dr. Isabelle Raymond as Vice President, Clinical Development
HSMN NewsFeed - 11 Apr 2018
Sysmex Inostics: OncoBEAM(TM) RAS CRC Liquid Biopsy Test Now Reimbursed in Germany by BARMER
Sysmex Inostics: OncoBEAM(TM) RAS CRC Liquid Biopsy Test Now Reimbursed in Germany by BARMER
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 6 Oct 2017
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 14 Aug 2017
Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 13 Jul 2017
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 4 Apr 2017
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
HSMN NewsFeed - 28 Jul 2016
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
HSMN NewsFeed - 11 Jan 2016
Iconic Therapeutics Closes Series C Financing With New and Existing Investors
Iconic Therapeutics Closes Series C Financing With New and Existing Investors
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
HSMN NewsFeed - 3 Nov 2015
Castle Biosciences Announces the Appointment of Federico Monzon, M.D., FCAP as Chief Medical Officer
Castle Biosciences Announces the Appointment of Federico Monzon, M.D., FCAP as Chief Medical Officer
HSMN NewsFeed - 19 Oct 2015
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
HSMN NewsFeed - 19 Oct 2015
Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
HSMN NewsFeed - 10 Sep 2015
iCAD Announces Appointment of Two Vice Presidents to Lead Cancer Detection Sales and Marketing Teams
iCAD Announces Appointment of Two Vice Presidents to Lead Cancer Detection Sales and Marketing Teams
HSMN NewsFeed - 16 Jul 2015
Immunocore Secures $320 Million (£205 Million) in Europe's Largest Private Life Sciences Financing
Immunocore Secures $320 Million (£205 Million) in Europe's Largest Private Life Sciences Financing
HSMN NewsFeed - 14 Jul 2015
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
HSMN NewsFeed - 29 May 2015
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
HSMN NewsFeed - 3 Mar 2015
Oraya Therapeutics' AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases
Oraya Therapeutics' AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases
HSMN NewsFeed - 23 Dec 2014
Personalized Cancer Vaccine Moves to Phase IIb Trial at Leading U.S. Cancer Hospitals
Personalized Cancer Vaccine Moves to Phase IIb Trial at Leading U.S. Cancer Hospitals
HSMN NewsFeed - 10 Sep 2014
Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
HSMN NewsFeed - 2 Jun 2014
Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
HSMN NewsFeed - 2 Jun 2014
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
HSMN NewsFeed - 19 Mar 2014
IsoRay Announces World's First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor
IsoRay Announces World's First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor
HSMN NewsFeed - 29 Jan 2014
Pacific Edge's Cxbladder(TM) Boosting Confidence in Bladder Cancer Detection
Pacific Edge's Cxbladder(TM) Boosting Confidence in Bladder Cancer Detection
HSMN NewsFeed - 13 Jan 2014
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
HSMN NewsFeed - 7 Jan 2014
Navidea Biopharmaceuticals Expands Lymphoseek(R) Global Commercialization Efforts
Navidea Biopharmaceuticals Expands Lymphoseek(R) Global Commercialization Efforts
HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
HSMN NewsFeed - 24 Oct 2013
Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study
Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 14 Oct 2013
Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
HSMN NewsFeed - 1 Oct 2013
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
HSMN NewsFeed - 1 Oct 2013
First urine-based cancer mutation monitoring test available from Trovagene
First urine-based cancer mutation monitoring test available from Trovagene
HSMN NewsFeed - 30 Sep 2013
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
HSMN NewsFeed - 22 Sep 2013
Nucletron, an Elekta Company, Introduces Esteya, Electronic Brachytherapy for Treating Skin Cancer
Nucletron, an Elekta Company, Introduces Esteya, Electronic Brachytherapy for Treating Skin Cancer
HSMN NewsFeed - 13 Sep 2013
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
HSMN NewsFeed - 26 Aug 2013
GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer
GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer
HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
HSMN NewsFeed - 21 Mar 2013
Results of Lymphoseek(R) Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology
Results of Lymphoseek(R) Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology
HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
HSMN NewsFeed - 28 Jan 2013
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
HSMN NewsFeed - 12 Dec 2012
Galderma, World’s Leading Company Focused Exclusively on Dermatology, Acquires Spirig
Galderma, World’s Leading Company Focused Exclusively on Dermatology, Acquires Spirig
HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
HSMN NewsFeed - 5 Nov 2012
iCAD Reports Significantly Improved Medicare Payment for Intraoperative Radiation Therapy
iCAD Reports Significantly Improved Medicare Payment for Intraoperative Radiation Therapy
HSMN NewsFeed - 29 Oct 2012
iCAD Reports Growing Adoption of Its Xoft Electronic Brachytherapy System by Leading U.S. Regional Hospitals
iCAD Reports Growing Adoption of Its Xoft Electronic Brachytherapy System by Leading U.S. Regional Hospitals
HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed - 16 Aug 2012
Lucid, Inc. Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
Lucid, Inc. Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 18 Jun 2012
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
HSMN NewsFeed - 5 Jun 2012
IsoRay Announces World's First Cesium-131 Mesh Treatment for Meningioma Brain Tumors
IsoRay Announces World's First Cesium-131 Mesh Treatment for Meningioma Brain Tumors
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 4 May 2012
Breastlink Medical Group to Offer iCAD’s Xoft Radiation Therapy System to Breast Cancer Patients
Breastlink Medical Group to Offer iCAD’s Xoft Radiation Therapy System to Breast Cancer Patients
HSMN NewsFeed - 30 Apr 2012
Mobile Skin Cancer Treatment Now Features Xstrahl Superficial Radiation System
Mobile Skin Cancer Treatment Now Features Xstrahl Superficial Radiation System
HSMN NewsFeed - 5 Apr 2012
Delcath Receives European Regulatory Approval for Second Generation Hemofiltration Cartridge
Delcath Receives European Regulatory Approval for Second Generation Hemofiltration Cartridge
HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 19 Mar 2012
Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
HSMN NewsFeed - 13 Feb 2012
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
HSMN NewsFeed - 22 Nov 2011
IsoRay Receives Final Regulatory Approval for GliaSite(R) Brain Cancer Treatment
IsoRay Receives Final Regulatory Approval for GliaSite(R) Brain Cancer Treatment
HSMN NewsFeed - 3 Nov 2011
IsoRay Announces Major International Distribution Agreement for GliaSite(R)
IsoRay Announces Major International Distribution Agreement for GliaSite(R)
HSMN NewsFeed - 25 Aug 2011
Celsion Announces the Appointment of Gary Renshaw, D.O., as Executive Medical Director
Celsion Announces the Appointment of Gary Renshaw, D.O., as Executive Medical Director
HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
HSMN NewsFeed - 22 Jul 2011
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.
HSMN NewsFeed - 12 Jul 2011
IsoRay Announces World's First Cesium-131 Treatment for Lung Cancer Using da Vinci Robotic Surgery System
IsoRay Announces World's First Cesium-131 Treatment for Lung Cancer Using da Vinci Robotic Surgery System
HSMN NewsFeed - 3 May 2011
Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
HSMN NewsFeed - 13 Apr 2011
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT Delivery System
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT Delivery System
HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
HSMN NewsFeed - 5 Jan 2011
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
HSMN NewsFeed - 22 Dec 2010
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
HSMN NewsFeed - 20 Dec 2010
Myriad Genetics Launches PANEXIA, New Predictive Test for Hereditary Pancreatic and Related Cancers
Myriad Genetics Launches PANEXIA, New Predictive Test for Hereditary Pancreatic and Related Cancers
HSMN NewsFeed - 6 Dec 2010
Delcath Submits CE Mark Technical File for Hepatic ChemoSAT Delivery System
Delcath Submits CE Mark Technical File for Hepatic ChemoSAT Delivery System
HSMN NewsFeed - 1 Dec 2010
Delcath Names Bernard R. Tyrrell as Senior Vice President for North American Sales and Marketing
Delcath Names Bernard R. Tyrrell as Senior Vice President for North American Sales and Marketing
HSMN NewsFeed - 15 Oct 2010
Mayo Clinic Finds Early Success with Laser that Destroys Tumors with Heat
Mayo Clinic Finds Early Success with Laser that Destroys Tumors with Heat
HSMN NewsFeed - 13 Oct 2010
IsoRay's Revolutionary Internal Radiation Therapy for Lung Cancers is Focus of National Study
IsoRay's Revolutionary Internal Radiation Therapy for Lung Cancers is Focus of National Study
HSMN NewsFeed - 7 Oct 2010
Spectral Molecular Imaging, Inc. Introduces Its Early Melanoma Detection Device SkinSpect(TM)
Spectral Molecular Imaging, Inc. Introduces Its Early Melanoma Detection Device SkinSpect(TM)
HSMN NewsFeed - 14 Jul 2010
Douglas G. Watson, Former CEO of Novartis Corporation, Joins Delcath Board of Directors
Douglas G. Watson, Former CEO of Novartis Corporation, Joins Delcath Board of Directors
HSMN NewsFeed - 22 Apr 2010
Delcath Systems Appoints Peter J. Graham as Executive Vice President and General Counsel
Delcath Systems Appoints Peter J. Graham as Executive Vice President and General Counsel
HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed - 1 Mar 2010
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
HSMN NewsFeed - 21 Jan 2010
IsoRay Announces World's First Cesium-131 Colon Cancer Treatment at Cornell Medical Center
IsoRay Announces World's First Cesium-131 Colon Cancer Treatment at Cornell Medical Center
HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
HSMN NewsFeed - 29 Oct 2009
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
HSMN NewsFeed - 21 Oct 2009
Antigenics Announces a Negative Vote From the CHMP on Oncophage(R) Marketing Application in Europe
Antigenics Announces a Negative Vote From the CHMP on Oncophage(R) Marketing Application in Europe
HSMN NewsFeed - 24 Jul 2009
NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
HSMN NewsFeed - 11 May 2009
DUSA Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
DUSA Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
HSMN NewsFeed - 29 Apr 2009
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
HSMN NewsFeed - 10 Apr 2009
Molecular Templates Inc. Secures $2.5 Million in Series A Financing from Sant Ventures
Molecular Templates Inc. Secures $2.5 Million in Series A Financing from Sant Ventures
HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
HSMN NewsFeed - 19 Nov 2008
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
HSMN NewsFeed - 18 Nov 2008
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
HSMN NewsFeed - 3 Oct 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
HSMN NewsFeed - 30 Sep 2008
Lucid Receives FDA Clearance to Market Its VivaScope(R) Reflective Confocal Microscope System in the U.S.
Lucid Receives FDA Clearance to Market Its VivaScope(R) Reflective Confocal Microscope System in the U.S.
HSMN NewsFeed - 12 Sep 2008
PhotoMedex Now Distributing Omnilux Photodynamic Therapy Line by Photo Therapeutics
PhotoMedex Now Distributing Omnilux Photodynamic Therapy Line by Photo Therapeutics
HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
HSMN NewsFeed - 7 Aug 2008
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
HSMN NewsFeed - 15 Jul 2008
Neoprobe Signs Non-Binding Letter of Intent for Lymphoseek European Distribution
Neoprobe Signs Non-Binding Letter of Intent for Lymphoseek European Distribution
HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
HSMN NewsFeed - 14 Jul 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 3 Jul 2008
Seven Major U.S. Cancer Institutions Order Hyperthermia Systems from BSD Medical
Seven Major U.S. Cancer Institutions Order Hyperthermia Systems from BSD Medical
HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
HSMN NewsFeed - 24 Jun 2008
Six Weeks of Radiation Therapy May Be Unnecessary for Many Breast Cancer Patients
Six Weeks of Radiation Therapy May Be Unnecessary for Many Breast Cancer Patients
HSMN NewsFeed - 10 Jun 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
HSMN NewsFeed - 3 Jun 2008
Provectus Pharmaceuticals Appoints Kelly M. McMasters, MD, PhD, to Board of Directors
Provectus Pharmaceuticals Appoints Kelly M. McMasters, MD, PhD, to Board of Directors
HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
HSMN NewsFeed - 8 Apr 2008
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
HSMN NewsFeed - 1 Apr 2008
Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
HSMN NewsFeed - 28 Jan 2008
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Additional items found! 453
Members Archive contains
453 additional stories matching:
melanoma
(Password required)
melanoma
(Password required)